ArticleSocial science & medicine (1982)2015
Peering into the pharmaceutical "pipeline": investigational drugs, clinical trials, and industry priorities.
Article in Social science & medicine (1982), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Treatment 'cultures', sexually transmitted infections and the rise of antimicrobial resistance.Sociology of health & illness · 2025Article
- Shifting patterns and competing explanations for infectious disease priority in global health agenda setting arenas.Health policy and planning · 2024Article
- Public health relevance of medicines developed under paediatric legislation in Europe and the USA: a systematic mapping study.BMJ paediatrics open · 2024Article
- Pipeline progress and portfolio management of the top 30 pharma companies over the past two decades.Journal of pharmaceutical policy and practice · 2023Article
- Testing psychosocial interventions in the contexts they are meant to be delivered.Journal of consulting and clinical psychology · 2023Article
- Patient Influencers: The Next Frontier in Direct-to-Consumer Pharmaceutical Marketing.Journal of medical Internet research · 2022Article
- Bioengineered Efficacy Models of Skin Disease: Advances in the Last 10 Years.Pharmaceutics · 2022Review
- The rise and fall of global health issues: an arenas model applied to the COVID-19 pandemic shock.Globalization and health · 2021Article
- Exploratory Analysis of the Factors Associated With Success Rates of Confirmatory Randomized Controlled Trials in Cancer Drug Development.Clinical and translational science · 2021Article
- Five insights from the Global Burden of Disease Study 2019.Lancet (London, England) · 2020Review
- Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.Lancet (London, England) · 2020 · on this mapArticle
- Why have Non-communicable Diseases been Left Behind?Asian bioethics review · 2020Article
- Exposing drug industry funding of UK patient organisations.BMJ (Clinical research ed.) · 2019Article
- Did relaxing clinical trial regulation enhance the stock of scientific knowledge in India? Not necessarily.PloS one · 2019Article
- Exceptional Risk: Healthy Volunteers' Perceptions of HIV/AIDS Clinical Trials.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- Beyond unequal access: Acculturation, race, and resistance to pharmaceuticalization in the United States.SSM - population health · 2018Article
- Autism genetics: opportunities and challenges for clinical translation.Nature reviews. Genetics · 2017Review
- "Just Advil": Harm reduction and identity construction in the consumption of over-the-counter medication for chronic pain.Social science & medicine (1982) · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
In spite of a growing literature on pharmaceuticalization, little is known about the pharmaceutical industry's investments in research and development (R&D). Information about the drugs being developed can provide important context for existing case studies detailing the expanding--and often problematic--role of pharmaceuticals in society. To access the pharmaceutical industry's pipeline, we constructed a database of drugs for which pharmaceutical companies reported initiating clinical trials over a five-year period (July 2006-June 2011), capturing 2477 different drugs in 4182 clinical trials. Comparing drugs in the pipeline that target diseases in high-income and low-income countries, we found that the number of drugs for diseases prevalent in high-income countries was 3.46 times higher than drugs for diseases prevalent in low-income countries. We also found that the plurality of drugs in the pipeline was being developed to treat cancers (26.2%). Interpreting our findings through the lens of pharmaceuticalization, we illustrate how investigating the entire drug development pipeline provides important information about patterns of pharmaceuticalization that are invisible when only marketed drugs are considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.